T. Rowe Price Investment Management Inc. Boosts Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• T. Rowe Price Investment Management Inc. increased its holdings in BioNTech SE by 61.5%, bringing its total to 86,154 shares valued at approximately $7.85 million as of the end of the most recent quarter.
• Other institutional investors, including Bank of New York Mellon Corp and Invesco Ltd., significantly boosted their stakes in BioNTech, with increases of 18,892.9% and 643.7% respectively during the first quarter.
• BioNTech's stock has performed strongly with a 102.6% year-over-year revenue increase, yet reported a loss of ($1.60) earnings per share, missing analyst expectations.

T. Rowe Price Investment Management Inc. boosted its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 61.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 86,154 shares of the company's stock after purchasing an additional 32,818 shares during the period. T. Rowe Price Investment Management Inc.'s holdings in BioNTech were worth $7,846,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. OneDigital Investment Advisors LLC purchased a new position in shares of BioNTech in the first quarter valued at about $288,000. GAMMA Investing LLC lifted its position in shares of BioNTech by 5,710.8% in the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock valued at $4,884,000 after acquiring an additional 52,711 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in shares of BioNTech in the fourth quarter valued at about $238,000. Allianz Asset Management GmbH increased its holdings in shares of BioNTech by 44.3% in the first quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company's stock worth $10,989,000 after purchasing an additional 37,075 shares during the last quarter. Finally, Cerity Partners LLC bought a new stake in shares of BioNTech in the first quarter worth about $357,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Price Performance

Shares of BioNTech stock traded down $1.60 on Friday, hitting $100.34. 318,526 shares of the company were exchanged, compared to its average volume of 927,897. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $131.49. The stock has a market capitalization of $24.12 billion, a price-to-earnings ratio of -62.71 and a beta of 1.23. The company has a 50-day moving average price of $109.79 and a 200 day moving average price of $105.18. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. During the same quarter in the prior year, the company posted ($3.36) earnings per share. The company's revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BNTX. Morgan Stanley boosted their price objective on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Leerink Partners set a $112.00 target price on BioNTech in a research report on Monday, June 2nd. JPMorgan Chase & Co. dropped their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Finally, HC Wainwright lowered their price target on BioNTech from $138.00 to $136.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Thirteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $135.80.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.